Belgian biopharmaceutical company Cardio3 Biosciences, which is backed by a consortium of venture capital firms, has announced that it is considering listing new shares in an IPO.
The company, which raised €19m last month from existing investors in the form of €7m in fresh equity and €12m as a conversion of convertible loans, hopes to raise new funds through an IPO on NYSE...
GP acquired a majority stake in French ingredients producer Solina in 2015
Delisting after three years values the equity of Moleskine at €506m
VC acquired a majority stake in the group in 2012 alongside Calliode partners
VC hopes the appointment will strenghten its potential in the IT projects field